Please Wait
Applying Filters...
menu
    • menu
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    ethyl 4-{13-chloro-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}piperidine-1-carboxylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 333Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    28/09/2024 Viatris
    U.S.A
    		 Kukjeon Pharmaceutical Co., Ltd. 20120504-6-C-286-07 Loratadine 2012-05-04 Mylan Laboratories Limited India Plot No. 14,99 & 100, IDA Pashamylaram Phase-II Patancheru, Sangareddy District-502307 Telangana, India
    28/09/2024 Viatris
    U.S.A
    		 Bayer Korea Ltd. 20120504-6-C-286-07(1) Loratadine 2022-11-14 Mylan Laboratories Limited India Plot No. 14,99 & 100, IDA Pashamylaram Phase-II Patancheru, Sangareddy District-502307 Telangana, India